MBAM
IRD

Mink Brook Asset Management’s Opus Genetics IRD Stock Holding History

Mink Brook Asset Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.69M Sell
590,552
-1,075,079
-65% -$3.72M 1.5% 16
2025
Q4 		$3.35M Buy
1,665,631
+427,684
+35% +$868K 2.12% 13
2025
Q3 		$2.04M Buy
1,237,947
+40,331
+3% +$50.1K 1.38% 17
2025
Q2 		$1.13M Buy
1,197,616
+387,536
+48% +$359K 0.98% 16
2025
Q1 		$795K Buy
+810,080
New +$905K 0.84% 19

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Mink Brook Asset Management's IRD Position: Q1 2026 in Review

Mink Brook Asset Management reduced its Opus Genetics (IRD) stake by 65% in Q1 2026, selling an estimated $3.72M and leaving 590,552 shares worth $2.69M. The position accounts for 1.5% of the portfolio, ranked #16.

Mink Brook Asset Management first reported a position in IRD in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.35M in Q4 2025. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Mink Brook Asset Management held 590,552 shares of Opus Genetics worth $2.69M as of Q1 2026.
  • Mink Brook Asset Management sold 1,075,079 Opus Genetics shares in Q1 2026, an estimated $3.72M.
  • Opus Genetics made up 1.5% of Mink Brook Asset Management's portfolio in Q1 2026, its #16 holding.
  • Mink Brook Asset Management first reported a position in Opus Genetics in Q1 2025 and has held it in 5 quarters since.
  • Mink Brook Asset Management's Opus Genetics position peaked at $3.35M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Mink Brook Asset Management's 13F filing for Q1 2026, filed 1 Apr 2026.